Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVISE: Dexmedetomidine for Septic Encephalopathy
NCT04076826Completed
- Sponsor
- Insel Gruppe
- Start
- Sep 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dexmedetomidine in sepsis-associated encephalopathy (SAE) (2 arms), sponsored by Insel Gruppe. Primary endpoint: S100 calcium-binding protein B at 48 hours. Started Sep 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
sepsis-associated encephalopathy (SAE)
Beyond the preview
Go deeper on NCT04076826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076826.